NCT05800197

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: Blokhin's Russian Cancer Research Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.

Detailed description

Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia. Nonrandomized, retrospective clincal trial Eligible postmenopausal women were treated with tamoxifen 20 mg, exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily before surgery or Eligible premenopausal women were treated with tamoxifen 20 mg, exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily in combination with ovarian suppression before surgery

Conditions

• Breast Cancer
• Neoadjuvant Endocrine Therapy

Interventions

Type	Name	Description
DRUG	Tamoxifen 20mg	Selective estrogen receptor modulator
DRUG	Anastrozole 1mg	Aromatase Inhibitor
DRUG	Letrozole 2.5mg	Aromatase Inhibitor
DRUG	Goserelin	Gonadotropin Releasing Hormone (GnRH) agonist
DRUG	Triptorelin	Gonadotropin Releasing Hormone (GnRH) agonist

Timeline

• Start date: 2014-04-15
• Primary completion: 2023-08-15
• Completion: 2025-01-15
• First posted: 2023-04-05
• Last updated: 2023-04-06

Locations

1 site across 1 country: Russia